Tumor-derived factors impaired motility and immune functions of dendritic cells through derangement of biophysical characteristics and reorganization of cytoskeleton

Cell Motility and the Cytoskeleton

Volumn 64, Issue 3, 2007, Pages 186-198

  Zeng, Zhu ^a,b   Xu, Xiaofeng ^a   Zhang, Yingyu ^a   Xing, Junjie ^a   Long, Jinhua ^a   Gu, Li ^a   Wang, Xianwei ^a   Sun, Dagong ^a   Ka, Weibo ^a   Yao, Weijuan ^a   Wen, Zongyao ^a   Chien, Shu ^c  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Biophysical characteristics and immune functions; Dendritic cells (DCs); Immune escape mechanism; Suppressive cytokines; Tumor microenvironment

Indexed keywords

CYTOKINE; INTERLEUKIN 12;

ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL ENERGY; CELL MOTILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOSKELETON; DENDRITIC CELL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MEMBRANE FLUIDITY; MICROENVIRONMENT; OSMOTIC FRAGILITY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY;

ACTINS; BIOPHYSICS; CELL MOVEMENT; CELL SURVIVAL; CYTOKINES; CYTOSKELETON; DENDRITIC CELLS; ENDOCYTOSIS; ENDOTHELIAL CELLS; FLUORESCENCE; FLUORESCENCE POLARIZATION; HUMANS; INTERLEUKIN-12 SUBUNIT P40; JURKAT CELLS; LYMPHOCYTE CULTURE TEST, MIXED; MICROSCOPY, CONFOCAL; NEOPLASM PROTEINS; OSMOTIC FRAGILITY; PHENOTYPE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SUBCELLULAR FRACTIONS;

EID: 33847212531     PISSN: 08861544     EISSN: 10970169     Source Type: Journal    
DOI: 10.1002/cm.20175     Document Type: Article

References (65)

1. Afsanch S, Jörg Z. 2005. Dendritic cells: Limited potential in immunotherapy. Int J Biochem Cell Biol 37:241-245.
2. Allavena P, Pienonti L, Longoni D. 1998. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 28(1):359-369.
3. Almand B, Resser JR, Lindman B. 2000. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6(5):1755-1766.
4. Austyn JM. 1996. New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med 183:1287-1292.
5. Azumi M. 1962. Fluorescence assay in biology and medicine. J Chem Phys 37:2413-2420.
6. Banchereau J, Steinman RM. 1998. Dendritic cells and the control of immunity. Nature 392:245-252.
7. Banchereau J, Palucka AK. 2005. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5:296-306.
8. Becker Y. 1992. Anticancer role of dendritic cells (DCs) in human and experimental cancers-A review. Anticancer Res 12:511-520.
9. Berry MN, Edwards AM, Barritt GJ, Burdon RH, Knippenberg PH, editors. 1991. Isolated Hepatocytes: Preparation, Properties and Application. Amsterdam: Elsevier. pp 18-58.
10. Burns S, Hardy SJ, Buddle J. 2004. Maturation of DCs is associated with changes in motile characteristics and adherence. Cell Motil Cytoskeleton 57:118-132.
11. Byrne SN, Halliday GM. 2002. Dendritic cells: Making progress with tumor regression. Immunol Cell Biol 80:520-530.
12. Cao XT. 1998. The clinical research advances and foundations of dendritic cells. J Chin Immunol 14(3):161-168.
13. Cella M, Sallusto F, Lanzavecchia A. 1997. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 9:10-16.
14. + T cells in vitro. Blood 91:4652-4661.
15. Chen K, Li D, Jiang YH, Yao WJ, Wang XJ, Wei XC, Gao J, Xie LD, Yan ZY, Wen ZY, Chien S. 2004. Influence of expressed TRAIL on biophysical properties of the human leukemic cell line Jurkat. Cell Res 14(2):161-168.
16. Cumberbatch M, Kimber I. 1995. TNF-α is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitization. Immunology 84:31-35.
17. Damon CS, Karla JD, Edward JC. 2004. Changes in the motility, morphology, and F-actin architecture of human dendritic cells in an in vitro model of dendritic cell development. Cell Motil Cytoskeleton 46:200-221.
18. de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ. 2003. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9:5091-5100.
19. D'Orazio TJ, Niederkorn JY. 1998. A novel role for TGF-β and IL-10 in the induction of immune privilege. J Immunol 160(5):2089-2098.
20. Dustin ML, Cooper JA. 2000. The immunological synapse and the actin cytoskeleton: Molecular hardware for T cell signaling. Science 1(1):23-29.
21. Evel-Kabler K, Chen SY. 2006. Dendritic cell-based tumor vaccines and antigen presentation attenuators. Mol Ther 13(5):850-858.
22. Gabrilovich DI. 2004. Mechanisms and functional significance of tumor-induced dendritic cell defects. Nat Rev Immunol 4(12):941-952.
23. Gabrilovich DI, Patterson S, Harvey JJ. 1995. Defects in the function of dendritic cells in marine retroviral infection. Adv Exp Med Biol 378:469-472.
24. Gabrilovich DI, Corak J, Ciernik IF. 1997. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3(3):483-490.
25. Gao TY, Ci YX. 2000. FTIR investigation of the interaction of tumors cells treated with caffeic acid and chlorogenic acid. Vib Spectrosc 24:225-231.
26. +cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. Int J Cancer 73(5):663-668.
27. Gu L, Jiang YH, Wang Y. 2005. TFAR19 gene changes biophysical behavior of murine erythroleukemia cells. Cell Biochem Biophys 43:355-363.
28. Jiang YH, Zeng Z, Sun DG, Ka WB, Wen ZY. 2005. Adhesion of monocyte-derived dendritic cells to human umbilical vein endothelial cells in flow field decreases upon maturation. Clin Hemorheol Microcirc 32(4):261-268.
29. Kalinski P, Hilkens GM, Snijder A, Snijdewint FG, Kapsenberg ML. 1997. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type2 cytokine production in maturing human naïve T helper cells. J Immunol 159:28-35.
30. Lanzavecchia A. 1996. Mechanism of antigen uptake for presentation. Curr Opin Immunol 8:328-354.
31. Lee WC, Chiang YJ, Wang HC. 2004. Functional impairment of dendritic cells caused by murine hepatocellular carcinoma. J Clin Immunol 24(2):145-153.
32. Le Gal J. 1993. Ultrastructural appraisal of the multidrug resistance in K562 and LR73 cell lines from FTIR. Cancer Res 53:3681-3686.
33. Le Gal J, Morjani H, Fardel O. 1994. Conformational changes in membrane proteins of multidrug-resistant K562 and primary rat hepatocyte cultures as studied by FTIR. Anticancer Res 14:1541-1548.
34. Liu KZ. 1998. Similarities between the sensitivity to 2-chlorodeoxyadenosine of lymphocytes from CLL patients and bryostatin 1-treated WSU-CLL cells: An infrared spectroscopic study. Cancer Lett 127:185-193.
35. Makarenkova VP, Shurin GV. 2003. Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells. J Neuroimmunol 145:55-67.
36. McBride MJ, Jung T, de Vries JE, Aversa G. 2002. IL-10 alters DCs function via modulation of cell surface molecules resulting in impaired T-cell responses. Cell Immunol 215:162-172.
37. Melif CJM. 2001. T-cell immunity against tumors, a delicate balancing act involving dendritic cells. Pathol Biol 49:498-499.
38. Moingeon P. 2001. Cancer vaccines. Vaccine 19:1305-1326.
39. Momti P, Leone BE, Zerbi A. 2004. Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell. J Immunol 172:7341-7349.
40. Nathan I. 1998. Alterations in membrane lipid dynamics of leukemic cells undergoing growth arrest and differentiation: Dependency on the inducing agent. Exp Cell Res 239:442-446.
41. Nestle FO, Farkas A, Conrad C. 2005. Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol 17:163-169.
42. Ninomiya T, Akbar SM, Masumoto T. 1999. Dendritic cells with immature phenoltype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 31(2):323-331.
43. Oyama T, Ran S, Ishida T. 1998. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. J Immunol 160(3):1224-1232.
44. Pantaloni D, Clainche CL, Carlier MF. 2001. Mechanism of actin-based motility. Science 292:1502-1506.
45. Parola AH. 1993. In: Shinitzky M, editor. Biomembranes, Physical Aspects 2. New York and Cambridge, p 159-277.
46. Peguet-Navarre J. 2003. Gangliosides from human melanoma tumors impair dendritic cell differentiation from nonocytes and induce their apoptosis. J Immunol 170:3488-3494.
47. Pinzon-Charry A, Maxwell T, Lopez JA. 2005. Dendritic cell dysfunction in cancer: A mechanism for immunosupression. Immunol Cell Biol 83:451-461.
48. Ramesh J, Salma A. 2001. Application of FTIR microscopy for the characterization of malignancy. H-ras tranfected murine fibroblasts as an example. J Biochem Biophys Methods 50:33-42.
49. Randolph GJ, Angeli V, Swartz MA. 2005. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 5:617-628.
50. Sattapom S, Robins A, Vassanasiri W. 2004. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother 53:510-518.
51. Schwaab T, Schned AR, Heaney JA. 1999. In vivo description of dendritic cells in human renal cell carcinoma. J Urol 162(2):567-575.
52. Shurin GV. 2001. Neuroblastoma derived gangliosides inhibit dendritic cells generation and function. Cancer Res 61:363-369.
53. Shurin GV, Yurkovestsky ZR, Shurin MR. 2003. Tumor-induced dendritic cell dysfunction. In: Ochoa A, editor. Mechanisms of Tumor Escape From the Immune Response. New York: Taylor and Francis, p 112-138.
54. Silvano S. 2005. Dendritic cell trafficking: More than just chemokines. Cytokine Growth Factor Rev 16:581-592.
55. Steinman RM. 1991. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-296.
56. Théry C, Amigorena S. 2001. The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol 13:45-51.
57. Thurnher M, Radmayr C, Ramoner R. 1996. Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 68(1):1-12.
58. Tourkova IL, Zoya RY, Michael RS, Galina VS. 2001. Mechanism of dendritic cell-induced T cell proliferation in primary MLR assay. Immunol Lett 78:75-82.
59. Tsujitani S, Kakeji YY, Watanabe A, 1990. Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 66(9):2012-2016.
60. van Kooyk Y, Geijteenbeek TBH. 2003. DCs-SIGN: Escape mechanism for pathogens. Nat Rev Immunol 3:697-709.
61. Vicente-Manzanares M, Sánchez-Madrid F. 2004. Role of the cytoskeleton during leukocyte responses. Nat Rev Immunol 4:110-122.
62. Winzler C, Rovere P, Rescigno M. 1997. Clinical applications of dendritic cells. J Exp Med 185:317-328.
63. Yao WJ, Gu L, Sun DG, Ka WB, Wen ZY, Chien S. 2003. Wild type p53 gene causes reorganization of cytoskeleton and difficult migration of murine erythroleukemia cells. Cell motil cytoskeleton 56:1-12.
64. +monocytes into dendritic cells. Cell Biochem Biophys 45(1):19-30.
65. Zou WP. 2005. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 5:263-274.